Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
Kevin Noonan
Advertisement
Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group.
Articles by Kevin Noonan
Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.
Advertisement
Latest Updated Articles
NIST Proposes Clarifications to Bayh-Dole March-in Rights RegulationsPublished: October 15th 2021 | Updated:
- The NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations
Published: September 2nd 2021 | Updated:
Patenting Prospects for Cell-Based TherapiesPublished: September 15th 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
